AZD0466 active in small cell lung cancer patient models
Posted: 21 April 2023 Starpharma announces AZD0466 results from a preclinical study in small cell lung cancer (SCLC) patient-derived xenograft (PDX) models. Starpharma’s partner, AstraZeneca, presented these results overnight at the American Association for Cancer Research (AACR) Annual Meeting.…
International partnership launches Monash University-Helmholtz lab to solve global oncology, cardiology and infectious disease challenges
Posted: 21 April 2023 Monash University has partnered with the Helmholtz-Zentrum Dresden-Rossendorf (HZDR), a member of the Helmholtz Association of German Research Centres to establish the Monash-Helmholtz Laboratory for Radio-Immuno-Theranostics (MHELTHERA) to enable clinical translation at a launch…
ANDHealth Partners with Chicago ARC to Bring Australian Digital Health Startups into the U.S. Market
Posted: 21 April 2023 Chicago ARC Executive Director Kate Merton and ANDHealth CEO and Managing Director Bronwyn Le Grice today announced an exciting new partnership to connect Australia’s best and brightest digital health companies with U.S. partners and…
DAYBUE (trofinetide) launched in US – Neuren earns US$40m
Posted: 19 April 2023 Neuren Pharmaceuticals reported that its North America partner Acadia Pharmaceuticals (NASDAQ: ACAD) has announced that DAYBUE™ (trofinetide) is now available for the treatment of Rett syndrome in adult and pediatric patients two years of…
DEP cabazitaxel Phase 2 clinical trial completes enrolment and treatment
Posted: 19 April 2023 Starpharma announces that it has completed enrolment and treatment of patients for the Phase 2 clinical trial of its investigational anticancer product DEP cabazitaxel. Encouraging efficacy signals, including significant tumour shrinkage and substantial tumour…
Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting
Posted: 19 April 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the initiation of an open-label Phase II trial evaluating eftilagimod…
First Patient Recruited to Cohort 3 of ACCENT Trial in Pancreatic Cancer
Posted: 19 April 2023 Amplia Therapeutics Limited is pleased to advise that dosing of the first patient in Cohort 3 of the Company’s ongoing Phase 1b/2a ACCENT clinical trial of FAK inhibitor AMP945 in pancreatic cancer has begun.…
Two New Deoxymab Patents Granted in the USA
Posted: 19 April 2023 Patrys Limited, a therapeutic antibody development company, is pleased to announce that the US Patent and Trademark Organisation has granted two patents that provide further intellectual property protection for Patrys’ deoxymab antibody technology until…
Ginkgo Bioworks and WARF Announce Partnership to Discover Next Generation GD2 CAR T-Cell Therapies
Posted: 19 April 2023 The Wisconsin Alumni Research Foundation (WARF), which has a mission of supporting research at the University of Wisconsin-Madison, and Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, today announced…
Ginkgo Bioworks and Syngenta Seeds Announce Collaboration to Develop New Traits for the Next Generation of Seed Technology
Posted: 19 April 2023 Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, and Syngenta Seeds, one of the world’s leading agricultural technology companies, announced a research partnership focused on screening a targeted genetic…
Former U.S. Secretary of Veterans Affairs Dr David Shulkin assumes advisory role with 4DMedical
Posted: 19 April 2023 Respiratory imaging technology disruptor 4DMedical Limited announces that Dr David Shulkin, MD, has assumed an advisory role within the company. As an accomplished and prominent health care system leader, physician, academic, and industry entrepreneur,…
Atmo Biosciences strengthens US focus with new board appointment and establishment of San Diego office
Posted: 17 April 2023 Atmo Biosciences, a company commercialising the world’s first ingestible gas-sensing capsule that provides insights into gut health and microbiome function, is strengthening its US focus with the appointment of experienced medical device executive Chris…
